Pipelines

Target ID
Hit-ID
Lead-ID
In Vitro PoC
In Vivo PoC
Lead Opt/Pre-IND
MDSC Target 1
Target ID
Hit-ID
Lead-ID
In Vitro PoC
In Vivo PoC
Lead Opt/Pre-IND

Title

32%
MDSC Target 2
Target ID
Hit-ID
Lead-ID
In Vitro PoC
In Vivo PoC
Lead Opt/Pre-IND

Title

32%
T-cell Target 1
Target ID
Hit-ID
Lead-ID
In Vitro PoC
In Vivo PoC
Lead Opt/Pre-IND

Title

25%
Ocular Melanoma
Target ID
Hit-ID
Lead-ID
In Vitro PoC
In Vivo PoC
Lead Opt/Pre-IND

Title

15%

Immuno-oncology

  IMM-IO-01

Immuneering is developing IMM-IO-01 as an agent that targets an immune regulatory receptor located on the surface of tolerizing M2 macrophages and myeloid-derived suppressor cells (MDSC). Inhibition of the receptor results in myeloid cell differentiation and helps promote activation and effector functions in T lymphocytes restoring anti-tumor immunity.

  IMM-IO-02

Immuneering is developing IMM-IO-02 as an agent that targets another immune regulatory receptor located on the surface of tolerizing M2 macrophages and myeloid-derived suppressor cells (MDSC), and on immature neutrophils. Inhibition of the receptor results in myeloid and neutrophil cell differentiation and helps promote activation and effector functions in T lymphocytes restoring anti-tumor immunity.

  IMM-IO-03

Immuneering is developing IMM-IO-03 as an accessory T cell checkpoint that blocks activation and function of tumor-reactive T cells. Inhibition of this checkpoint helps promote T cell activation and is being evaluated alone and in combination with related immune checkpoint inhibitors as a strategy to restore effective tumor immunotherapy.

  IMM-IO-04

Immuneering is developing IMM-IO-04 for uveal (ocular) melanoma. IMM-IO-04 is a novel small molecule inhibitor being developed to inhibit one of the most highly expressed genes in poor risk uveal melanoma cells. Targeting this gene utilizes Immuneering’s disease cancelling technology to restore normal gene function to reverse the neoplastic phenotype in ocular melanoma cells.